Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-06-01 DOI:10.2217/pgs-2023-0018

Saba Maghari, Tyler Gallo, Salvador Rivas, Alexander German, Minh Q Nguyen Le, Hamed Abbaszadegan, Mark A Zubriski, Craig W Heise, Noel D Landas

{"title":"Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.","authors":"Saba Maghari, Tyler Gallo, Salvador Rivas, Alexander German, Minh Q Nguyen Le, Hamed Abbaszadegan, Mark A Zubriski, Craig W Heise, Noel D Landas","doi":"10.2217/pgs-2023-0018","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the prevalence of medications with actionable pharmacogenomic (PGx) safety and efficacy recommendations in patients receiving care from the Veterans Health Administration. Materials & methods: Outpatient prescription data from 2011 to 2021 and any documented adverse drug reactions (ADRs) were reviewed for those who received PGx testing at one Veterans Administration location between November 2019 and October 2021. Results: Among the reviewed prescriptions, 381 (32.8%) were associated with an actionable recommendation based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) prescribing guidelines, with 205 (17.7%) for efficacy concerns and 176 (15.2%) for safety concerns. Among those with a documented ADR for a PGx-impacted medication, 39.1% had PGx results that aligned with CPIC recommendations. Conclusion: Medications with actionable PGx recommendations for safety and efficacy concerns are received with similar frequency, and most patients who have undergone PGx testing at the Phoenix Veterans Administration have received medications that may be impacted by PGx testing.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the prevalence of medications with actionable pharmacogenomic (PGx) safety and efficacy recommendations in patients receiving care from the Veterans Health Administration. Materials & methods: Outpatient prescription data from 2011 to 2021 and any documented adverse drug reactions (ADRs) were reviewed for those who received PGx testing at one Veterans Administration location between November 2019 and October 2021. Results: Among the reviewed prescriptions, 381 (32.8%) were associated with an actionable recommendation based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) prescribing guidelines, with 205 (17.7%) for efficacy concerns and 176 (15.2%) for safety concerns. Among those with a documented ADR for a PGx-impacted medication, 39.1% had PGx results that aligned with CPIC recommendations. Conclusion: Medications with actionable PGx recommendations for safety and efficacy concerns are received with similar frequency, and most patients who have undergone PGx testing at the Phoenix Veterans Administration have received medications that may be impacted by PGx testing.

查看原文本刊更多论文

处方药与可行的药物基因组学建议在退伍军人健康管理局的病人。

目的:评估在接受退伍军人健康管理局护理的患者中，具有可操作药物基因组学(PGx)安全性和有效性建议的药物的流行情况。材料和方法:对2019年11月至2021年10月期间在退伍军人管理局一个地点接受PGx检测的患者，回顾了2011年至2021年的门诊处方数据和任何记录在案的药物不良反应(adr)。结果:在审查的处方中，381张(32.8%)与基于临床药物遗传学实施联盟(CPIC)处方指南的可操作建议相关，其中205张(17.7%)与疗效相关，176张(15.2%)与安全性相关。在记录有PGx影响药物不良反应的患者中，39.1%的PGx结果符合CPIC的建议。结论:在安全性和有效性方面，具有可操作的PGx建议的药物接受频率相似，并且在凤凰城退伍军人管理局接受PGx检测的大多数患者接受的药物可能受到PGx检测的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.